« Zurück
Startseite /
Verapamil (hydrochloride)

Verapamil (hydrochloride)

ArtNr	HY-A0064-10mM
Hersteller	MedChem Express
CAS-Nr.	152-11-4
Menge	10 mM/1 mL
Quantity options	10 mM/1 mL 1 g 500 mg 5 g
Kategorie	Metabolism Cholesterol & Lipid Metabolism Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.98
Citations	[1]Gowarty JL, et al. Verapamil as a culprit of palbociclib toxicity. J Oncol Pharm Pract. 2019 Apr;25(3):743-746.\|[2]Krikler DM. Verapamil in arrhythmia. Br J Clin Pharmacol. 1986;21 Suppl 2:183S-189S.\|[3]Zhou P, et al. Anti-arrhythmic effect of Verapamil is accompanied by preservation of cx43 protein in rat heart. PLoS One. 2013 Aug 12;8(8):e71567.\|[4]Rehnqvist N,et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996 Jan;17(1):76-81.\|[5]Kubo Y, et al. Blood-to-Retina Transport of Fluorescence-Labeled Verapamil at the Blood-Retinal Barrier. Pharm Res. 2018 Mar 12;35(5):93. Biochem Biophys Res Commun. 2020 Jan 15;521(3):596-602.\|Cancer Cell Int. 2021 Feb 16;21(1):108.\|Cancer Cell. 2017 Apr 10;31(4):501-515.e8. \|Cancer Res Commun. 2024 Apr 9;4(4):1024-1040.\|Cancer Sci. 2018 Apr;109(4):1135-1146. \|Cancers (Basel). 2021 Aug 6;13(16):3978.\|Cell Calcium. 2020 May;87:102171.\|Cell Stem Cell. 2023 Apr 6;30(4):378-395.e8.\|Comp Biochem Physiol C Toxicol Pharmacol. 2024 Jul 20:109980.\|Faculty of Pharmacy in Hradec Králové. Department of Pharmacology and Toxicology. Charles University 2019 Apr.\|Food Funct. 2021 Aug 10.\|Inflammopharmacology. 2023 Mar 28.\|J Pharm Anal. 2020 Apr;10(2):178-186.\|Mol Cell Endocrinol. 2019 Aug 20;494:110490. \|Pharm Biol. 2019 Dec;57(1):477-484.\|Phytomedicine. 2019 Mar 15;56:175-182. \|PLoS Biol. 2024 Mar 25;22(3):e3002565.\|Preprints. 2024 Jun 12.\|SSRN. 2024 Jun 4.\|Toxicol Appl Pharmacol. 2019 Apr 1;368:18-25.\|Toxicol Res Appl. 2018, 2:239784731880115.\|Toxicol Res Appl. September 25, 2018.\|Université de Lausanne. 2024 Feb 7.\|Xenobiotica. 2019 Dec;49(12):1485-1493. \|ACS Appl Nano Mater. 2025 Jan 21.\|Adv Mater. 2023 Sep 27:e2211980.\|Antibiotics (Basel). 2022 Jul 26;11(8):1005.\|Bioact Mater. 2021 Apr 21;6(11):4073-4082.\|Biochem Biophys Res Commun. 2023 Nov 24, 149314.\|Biochem Biophys Res Commun. 2024 Jan 8:691:149314.\|Biomed Chromatogr. 2024 Aug 17:e5984.\|Biomed Pharmacother. 2020 Sep;129:110506.\|Biomed Pharmacother. 2024 Oct 13:180:117568.\|Biomed Pharmacother. 2024 Oct 28:180:117603.\|Biomed Res Int. 2021 May 15.\|BMC Cancer. 2025 Jan 7;25(1):24.\|Br J Pharmacol. 2021 Jul 3.\|Braz J Med Biol Res. 2024 Jul 1:57:e13357.\|Cell Commun Signal. 2024 Jun 13;22(1):325.\|Eur J Pharmacol. 2021 Oct 7;174552.\|Eur J Pharmacol. 2022 Oct 25;175343.\|Eur J Pharmacol. 2024 Feb 21:176431.\|FEBS J. 2024 Jul;291(14):3249-3266.\|Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8.\|Int J Mol Sci. 2024 Oct 22;25(21):11346.\|Int J Mol Sci. 2025 Jan 6;26(1):412.\|J Med Chem. 2021 Mar 11;64(5):2725-2738.\|J Orthop Surg Res. 2024 Feb 19;19(1):147.\|Microbiol Spectr. 2023 Dec 4:e0251023.\|Mol Pharm. 2025 Jan 8.\|Nat Commun. 2024 Jun 19.\|Neurochem Res. 2022 Dec 8.\|Pak J Pharm Sci. 2022 Mar;35(2):571-578.\|Pak J Pharm Sci. 2022 Mar;35(2):587-594.\|Pestic Biochem Physiol. August 2022, 105170.\|Pharmacol Res Perspect. 2022 Feb;10(1):e00928.\|Research (Wash D C). 2024 Feb 21.\|Research Square Preprint. 2020 Dec.\|Research Square Preprint. 2020 Oct.\|Research Square Print. 2022.\|SSRN. 8 Nov 2022
Smiles	[H]Cl.COC1=CC=C(C(C#N)(C(C)C)CCCN(CCC2=CC=C(OC)C(OC)=C2)C)C=C1OC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	(±)-Verapamil (hydrochloride),CP-16533-1 (hydrochloride)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Calcium Channel; Cytochrome P450; P-glycoprotein
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	491.06
Product Description	Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].
Manufacturer - Research Area	Cardiovascular Disease; Cancer
Solubility	DMSO: 58.33 mg/mL (ultrasonic)\|H2O: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling
Isoform	CYP3
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-A0064-10mM-safety-datasheet.pdf